Clinical Trial Update: Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating universal CAR-T cells for refractory autoimmune diseases of the nervous system; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy
• Multiple Sclerosis
• Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorders

Drugs mentioned

• Universal CAR-T Cells (universal CAR-T cell therapy)

Snippet

Sponsor: Xuanwu Hospital, Beijing | Conditions: Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized | EARLY_Phase 1 | Status: NOT_YET_RECRUITING